1. Palbociclib FDA prescribing information, 2019, (n.d.). 〈https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207103s008lbl.pdf〉 (accessed February 10, 2023).
2. Ribociclib FDA prescribing information, 2019, (n.d.). 〈https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209092s004lbl.pdf〉 (accessed February 10, 2023).
3. Abemaciclib FDA prescribing information, 2021, (n.d.). 〈https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208716s006s007s008lbl.pdf〉 (accessed February 10, 2023).
4. CDK4/6 inhibitors in breast cancer treatment: Potential interactions with drug, gene, and pathophysiological conditions;Roncato;Int J Mol Sci.,2020
5. Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure;Roncato;Biomed. Pharmacother.,2023